PPCBHealthcare · BiotechnologyPPCB Stock Forecast: Propanc Biopharma, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 1 Aug 2026 — in the lower half.
PPCB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Propanc Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Propanc Biopharma, Inc. — and when they’d sell — is the membership.
PPCB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PPCB, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PPCB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Propanc Biopharma, Inc. (PPCB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 0.1×
- EV / EBITDA
- −0.2×
Cheaper than 74% of US stocks
Cheaper than 90% of US stocks
Cheaper than 63% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −127.0%
- Return on assets
- −62.3%
- Dividend yield
- —
Higher than 11% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PPCB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| PPCBPropanc Biopharma, Inc. | $2.3M | 43 |
| LABTLakewood-Amedex Biotherapeutics, Inc. | $3.5M | 23 |
| REVBRevelation Biosciences, Inc. | $3.7M | 11 |
| ENSCEnsysce Biosciences, Inc. | $3.7M | 43 |
| XRTXXORTX Therapeutics, Inc. | $3.8M | 22 |
| ERNAErnexa Therapeutics, Inc. | $3.8M | 25 |
| CELZCreative Medical Technology Holdings, Inc. | $3.1M | 35 |
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PPCB appears on the weeks it earns a place.
Frequently asked questions about PPCB stock
How does Ticker Nerd's model rank PPCB?
As at 1 Aug 2026, Propanc Biopharma, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).
What is the PPCB stock forecast for 2030?
No analyst covering Propanc Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PPCB are extrapolating price history, which says nothing about the business.
What does Propanc Biopharma, Inc. do?
Propanc Biopharma Inc. is a biopharmaceutical company focused on the development of novel cancer treatments.
About Propanc Biopharma, Inc.
Propanc Biopharma Inc. is a biopharmaceutical company focused on the development of novel cancer treatments. The primary function of the company is to research and develop therapeutic solutions specifically targeting cancerous tumors. Its innovative approach involves proenzyme therapy, which utilizes proenzymes or inactive precursors of enzymes, as a potential solution to treating a variety of cancer types by targeting and inhibiting cancerous cells. The biotechnology sector recognizes Propanc Biopharma for its pioneering work in advancing methods to prevent tumor recurrence and metastasis. The company's efforts target diseases with high unmet medical needs, aiming to improve patient outcomes with fewer side effects compared to conventional treatment options. Propanc Biopharma plays a significant role in the healthcare and life sciences sectors, contributing to the ongoing evolution of cancer treatment strategies. Operating within a competitive and rapidly advancing industry, Propanc Biopharma is a part of the broader movement towards innovative cancer therapies that redefine treatment paradigms and offer hope to patients worldwide.
CEO Mr. James Nathanielsz · 1 employees · Australia · https://www.propanc.com